Senate Concurrent Resolution 51 designates the month of May 2025 as Cystic Fibrosis Awareness Month in California. The resolution recognizes the disease’s public-health burden, encourages early diagnosis and access to quality care, and affirms support for research and psychosocial services for people with cystic fibrosis and their families.
The measure is symbolic: it contains no appropriation or regulatory change. Its practical value lies in signaling legislative priorities to state agencies, health-care providers, research funders, and advocacy organizations—giving those groups a formal hook for outreach, education, and fundraising activities.
At a Glance
What It Does
SCR 51 proclaims a month-long observance, recites epidemiological and scientific findings about cystic fibrosis, highlights the Cystic Fibrosis Research Institute (CFRI), and urges action on early diagnosis, care access, and research. It requests the Secretary of the Senate to transmit copies of the resolution for distribution.
Who It Affects
Patients with cystic fibrosis, their families, CF care centers, nonprofit advocates (notably CFRI), newborn screening programs, and public health communicators in California will be the primary audiences. The resolution does not create obligations for insurers, providers, or state programs.
Why It Matters
Although ceremonial, the resolution provides a public-policy signal that can be used to coordinate education campaigns, influence philanthropic and foundation attention, and justify outreach by state health officials and CF clinics. For advocates, it is a low-cost tool to amplify calls for screening improvements and research support.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
SCR 51 is a one-page concurrent resolution that uses a conventional legislative structure: a string of “whereas” findings followed by several short resolving clauses. The findings summarize the state of cystic fibrosis care and research—pointing to progress in therapies, ongoing mortality and morbidity, carrier prevalence, and gaps in newborn screening for rare CFTR mutations.
The text also spotlights the Cystic Fibrosis Research Institute and its role in funding research and supporting families.
The operative clauses do three things: they formally declare the month of May 2025 as Cystic Fibrosis Awareness Month; they express the Legislature’s support for early diagnosis, access to quality care, psychosocial support, and continued research toward a cure; and they direct the Secretary of the Senate to transmit copies of the resolution to the author for distribution. The resolution explicitly contains no funding directive or regulatory mandate.Because the measure is a concurrent resolution, it does not amend statutes, change program eligibility, or create any enforceable duties for state agencies or private parties.
Instead it creates a legislative posture—a public acknowledgement that the Legislature recognizes CF as a medical and social issue and that it supports awareness and research efforts. That posture can be leveraged by nonprofits, care centers, and public-health communicators to coordinate events, recruit volunteers, and justify grant proposals.Practically, the resolution is most useful as a communications and advocacy device.
Health departments and CF centers commonly use proclamations like this to anchor campaigns, secure media coverage, and align partner activities (awareness events, screening drives, fundraising). It does not, however, require the state to expand newborn screening panels, allocate research dollars, or change clinical standards; any such follow-on would need separate statutory, budgetary, or regulatory action.
The Five Things You Need to Know
The resolution formally designates an awareness month—May 2025—for cystic fibrosis in California.
SCR 51 identifies and commends the Cystic Fibrosis Research Institute (CFRI), a private nonprofit founded in 1975, as a statewide resource.
The Legislature included epidemiological and clinical findings in the preamble to justify awareness and research priorities, rather than creating policy changes.
The resolution contains no appropriation and was filed with the Secretary of State on July 3, 2025 (Chapter 114); it therefore imposes no fiscal obligations.
It directs the Secretary of the Senate to transmit copies of the resolution to the author for appropriate distribution, a standard transmittal step for ceremonial measures.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Legislative findings and evidence base
This section compiles health statistics, survival metrics, carrier prevalence, recent therapeutic advances, and screening limitations to build the case for an awareness month. By embedding specific data (for example, survival improvements and median age of death), the findings give advocates clear, legislatively endorsed talking points for outreach and fundraising.
Proclamation of Cystic Fibrosis Awareness Month
This clause is the operative proclamation designating May 2025 as Cystic Fibrosis Awareness Month in California. It's a declarative statement with no regulatory force: it creates recognition but not new legal duties, funding, or program changes.
Policy endorsements: awareness, diagnosis, care, and research
These sentences express the Legislature’s support for public education, early diagnosis, access to quality care, psychosocial support, and research. They function as policy direction in the sense of public posture—useful for agencies and grantmakers—but do not compel action from the Departments of Public Health, Health Care Services, or insurers.
Transmittal to the author
This administrative clause instructs the Secretary of the Senate to send copies of the resolution to the author for distribution. It is a formal step that enables the author and allied organizations to circulate the proclamation to stakeholders, media, and partner organizations.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Cystic Fibrosis Research Institute (CFRI): The resolution names and endorses CFRI, giving the nonprofit an official, state-level endorsement it can use in outreach, fundraising, and partnership development.
- People with cystic fibrosis and their families: Increased public visibility can translate to greater community support, easier fundraising for services, and higher public awareness of symptoms and testing options.
- CF care centers and clinicians: Proclamation-driven awareness campaigns can help clinics recruit patients for screening, clinical trials, and multidisciplinary care coordination.
- Advocacy organizations and funders: State recognition provides a timing and messaging hook that helps nonprofits run successful awareness and donor campaigns during May.
Who Bears the Cost
- Secretary of the Senate and legislative staff: Minimal administrative time to process and distribute copies of the resolution and to coordinate any ceremonial logistics.
- Nonprofit and clinical partners asked to respond: CF centers and advocacy groups may feel pressure to mount events or educational efforts around the month without commensurate funding.
- State public-health communicators: If agencies choose to align messaging with the proclamation, they may reallocate limited outreach resources to CF-related materials during the month.
Key Issues
The Core Tension
The central dilemma is symbolic recognition versus substantive remedy: the resolution raises awareness and political salience for cystic fibrosis—useful for advocacy and outreach—while offering no direct funding, regulatory changes, or enforcement mechanisms to address the screening gaps, treatment access issues, and disparities it documents.
The resolution creates a public-policy signal without binding effect: it neither authorizes spending nor modifies statute or regulation. That makes it a low-cost tool for awareness but a weak instrument for addressing the substantive gaps the findings identify—notably newborn screening limitations and racial and ethnic disparities in diagnosis.
Turning recognition into concrete change (expanded screening panels, insurance coverage mandates, targeted public-health programs) would require separate legislation, regulatory amendments, or budgetary allocations.
There is also a risk of misaligned expectations. Patients and families may reasonably expect that legislative recognition presages action on screening equity, access to cutting-edge therapies, or increased state support; the resolution does none of these.
Practically, the resolution shifts the labor of converting awareness into services onto stakeholders (nonprofits, clinics, agencies) without providing new resources. Finally, singling out a named private nonprofit (CFRI) is politically normal in proclamations but raises questions about the selection criteria and whether other organizations representing different communities or perspectives received comparable attention.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.